Jianfeng Group Lin2016 -011 (Related Transaction of Capital Increase of Jianfeng Pharmaceutical)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2016-011
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Related Party Transactions of Capital Increase in Jianfeng Pharmaceutical
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Overview of 1. Related Party Transactions
(I) On April 5, 2016 , the board of directors of Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a holding subsidiary of the Company, made a resolution, it is proposed to use the audited consolidated statement at the end of 2015 attributable to the owner of the parent company equity 30137.64 yuan as the basis for the monetary capital increase, the total amount of this capital increase is 100 million yuan. The Company holds a 99.16 equity interest in Peak Pharmaceuticals, and the amount of capital increase enjoyed by the Company is $99.16 million. Jinhua Tongji State-owned Assets Investment Co., Ltd. (hereinafter referred to as "Tongji State Investment") holds a 0.84 per cent stake in Jianfeng Pharmaceutical, and the amount of capital increase enjoyed by Tongji State Investment is 840000 yuan.
(II) Tongji Guotou holds 16.15 equity of the company and is the controlling shareholder of the company. Mr. Jiang Xiaomeng, chairman of the company, is also a director of Tongji Guotou. According to the relevant provisions of the Shanghai Stock Exchange Stock Listing Rules, Tongji Guotou is a related legal person of the company, and joint investment with related parties is a related transaction.
(III) the amount of this related party transaction is 9916 yuan, exceeding 30 million yuan, but it does not reach 5% of the absolute value of the company's audited net assets in 2015. this related transactions do not constitute a major asset restructuring of the listing Corporation's major asset restructuring management approach.
2. Related Party Introduction
1 , Name: Jinhua Tongji State-owned Assets Investment Co., Ltd.
2 , Nature of Enterprise: Limited Liability Company (Wholly State-owned)
3 , Place of Registration: no. 64 4
, 1st floor, No. 1389 Danxi Road, Jinhua City, Zhejiang Province, main office location: No. 695 , 1st floor, No. 1389 Danxi Road, Jinhua City, Zhejiang Province, legal representative: Liu Bo
6 , registered capital: RMB 9500 Yuan
7 , main business: general business items: authorized investment and operation of state-owned assets.
8 , Main Financial Indicators of Related Persons in Recent Year
As of December 31, 2015 , Tongji Guotou had total assets of 358.7316 million yuan, net assets of 342.4002 million yuan and net profit of 14.8026 million yuan.
Basic Information of 3. Jianfeng Pharmaceutical
, Basic Information of Transaction Target
(1 ) Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
(2 ) Enterprise Nature: Limited Liability Company
(3 ) Registration Place: main office location of
(4 ) on the second floor of X02 office quality inspection building, No. 58 Gaofan section, Baitang downline, Wucheng district, Jinhua city, Zhejiang province:
(5 ) on the fourth-fifth floor of Jianfeng building, No. 88 Wujiang east road, Jinhua city, Zhejiang province legal representative: Jiang Xiaomeng
(6 120) registered capital: RMB 149.07 million yuan
(7) main business: drug research and development and production (operating with valid license); Import of raw and auxiliary materials for production and scientific research; Imported mechanical equipment, instruments and spare parts. (For projects subject to approval according to law, business activities can only be carried out after approval by relevant departments)
2, main financial data of the transaction target (unit: ten thousand yuan)
subject
2015 # December 31, 142 |
total assets |
| 104765.48 |
total liabilities |
| 70945.02 |
Ownership of Parent Company Owner's Equity |
| 30137.64 |
Asset-Liability Ratio |
| 67.72% |
|
| Year | Operating Income |
| 113292.85 |
Net Profit Attributable to Owner of Parent Company |
| 5924.42 |
Principles and Methods for Price Determination of (I) Related Party Transactions
This capital increase is to be based on the owner's equity attributable to the parent company after the annual audit of Jianfeng Pharmaceutical 2015 .
(II)'s total capital increase this time is 10,000
.49 million yuan, and the company enjoys the capital increase right of 99.16 million yuan according to its shareholding ratio. Tongji Guotou enjoys the capital increase right of 840000 yuan according to its shareholding ratio. If both parties are fully funded, after the completion of the capital increase, the registered capital of Jianfeng Pharmaceutical will increase to 198.53 million yuan, of which Jianfeng Pharmaceutical will account for 99.16 percent and Tongji Guotou will account for 0.84 percent.The amount of capital increase subscribed by the (III) capital increase party shall be remitted to Jianfeng Pharmaceutical's account before June 30, 2016
.5. the purpose of the related party transaction and its impact on the listed company
Jianfeng Pharmaceutical is a controlling subsidiary of the company, and its pharmaceutical business is one of the company's two main businesses. With the continuous expansion of the development scale, the demand for funds is also increasing, especially after the investment of Jinxi project, the debt ratio of Jianfeng Pharmaceutical is on the high side, the capital increase of Jianfeng Pharmaceutical will help improve its asset structure, enhance its strength and competitiveness, and will contribute to the healthy and sustainable development of the company's pharmaceutical industry.
6. the review procedure to be performed for the related party transaction
On April 8, 266, 2016 , the company held the 6th meeting of the 9th board of directors, and all eight directors of the company attended the meeting in person. Mr. Jiang Xiaomeng, the related director, avoided voting on the proposal, which is in line with the relevant provisions of the Company Law and the Articles of Association of the company, the resolutions made are legal and valid. After deliberation and voting, the board of directors deliberated and passed the "related party transaction proposal on capital increase of Jianfeng pharmaceutical" with 7 votes in favor, 0 against and 0 abstention. It was agreed that the company would invest 99.16 million yuan to increase the capital of Peak Pharmaceuticals.
The amount of this related party transaction has not reached 5% of the absolute value of the audited net assets of the company in 2015
. According to the company's "Articles of Association", it does not need to be submitted to the general meeting of shareholders for approval. Beforethe board of directors, the company reported to the independent directors, and the independent directors made a prior approval statement, believing that the capital increase price of the related party transaction was determined on the basis of the audited net assets and enjoyed the capital increase right according to the shareholding ratio of each shareholder, and that the company could ensure that its share of equity would not be reduced after participating in the capital increase. After the implementation of the related party transaction, it will effectively optimize the asset structure of the invested company, enhance the strength of the enterprise, enhance the competitiveness, and ensure the sustainable and healthy development of the enterprise. The above related party transactions did not harm the interests of the company and shareholders, and agreed to submit the proposal to the 6th 275 meeting of the ninth board of directors of the company for deliberation. The independent directors expressed their independent opinions on the resolution made by the board of directors, and believed that the formation of the resolution complied with the "Company Law", the "Articles of Association" and other relevant provisions, and did not harm the interests of small and medium shareholders.
The audit committee of the company's board of directors issued a written review opinion on the related transaction, and believed that the relevant information on the related transaction was complete and the company's management had conducted comprehensive communication with it. The related party transaction belongs to the normal economic behavior of the company and meets the needs of the company's operation and development; the price of capital increase is determined according to the audited net assets, and the capital increase right is enjoyed according to the shareholding ratio of each shareholder. After the capital increase, the company's equity share of the invested unit will not decline; the transaction follows the principles of fairness, impartiality, voluntariness and good faith, and does not harm the interests of the company and shareholders.
Tongji Company's participation in this capital increase still needs to be approved by its competent authorities and departments.6. Online Announcement Annex
(I) Statement Approved in advance by Independent Directors
(II) Independent Director Opinion Signed and Confirmed by Independent Directors
(III) Written Review Opinion of Audit Committee of Board of Directors on Related Party Transactions
Financial Statements and Audit Report of (IV) Jianfeng Pharmaceutical
hereby announce
April 12, 2016
More information
Shanghai Bronze Award for Outstanding Invention Went in North Carolina
News from this newspaper The results of the 31st Shanghai Excellent Invention Trial jointly organized by the Shanghai Federation of Trade Unions, Shanghai Intellectual Property Office, Shanghai Municipal Committee of the Communist Youth League, Shanghai Science and Technology Association, and Shanghai Invention Association were evaluated a few days ago. The "Quality Improvement and Industrialization Optimization of Erlotinib Hydrochloride and Its Advanced Intermediates" declared by Technology Co., Ltd. won the bronze award. Erlotinib hydrochloride is a targeted therapy drug for the treatment of non-small cell lung cancer, which can prolong the survival time and improve the quality of life of lung cancer patients. It can target and specific sites of action to kill tumor cells, and has little impact on normal tissues. It belongs to the biological and new medical technology in the field of high-tech supported by the state. In this invention, 6,7-dimethoxyquinazoline -4-one, 4-chloro -6,7-di (2-methoxyethoxy) quinazoline and 3-aminophenylacetylene are important intermediates of erlotinib hydrochloride, which is also an important intermediate of icotinib hydrochloride, the first new anti-tumor drug of tinib in China. The invention designs and adopts a new synthesis process route, which can effectively reduce the cost of raw materials, the reactions are mostly aqueous phase reactions, energy consumption and three waste emissions are reduced by about 35%, industrialization conditions are optimized, product quality is improved, and it is applied to Industrialized mass production is conducive to the production of high-quality and low-cost erlotinib hydrochloride drugs and reduces the economic burden of patients. The Shanghai Excellent Invention Trial was founded in 1987. It is an important science and technology award approved by the Shanghai Municipal Government. It not only strongly promoted the majority of employees to carry out invention and creation activities based on their posts, but also improved the order.
2020
07-31
Jiang Xiaomeng was selected as one of the top ten news figures in the building materials industry. "China Building Materials" magazine published an exclusive interview in August. The 8th issue of 2019 "China Building Materials" magazine published a few days ago. In the "Exclusive Perspective" column, it published an exclusive interview with Jiang Xiaomeng, the top ten news figures in the building materials industry in 2018, the party secretary and chairman of the group company. The selection of the top ten news figures in the national building materials industry initiated by "China Building Materials" magazine has established nearly a hundred shining figures in the industry since 1999, which has attracted widespread attention in the industry. The selection of the top ten news figures in the building materials industry in 2018 is described as follows: Jiang Xiaomeng is a scholar and practical outstanding entrepreneur. In 2018, with his strategic thinking of insight into the future, he united and led cadres and employees at all levels of Jianfeng Group to actively adapt to the new economic normal, focusing on deepening supply-side structural reforms, the "Belt and Road" initiative, and vigorously advocating corporate transformation and upgrading and high-quality development. Work, seize opportunities, reform and innovate, and achieve historic new achievements in the development of the peak 60 years. The group's overall economic efficiency and development quality have been significantly improved. In recent years, under the leadership of Jiang Xiaomeng, Jianfeng Group has seized the opportunity to join forces with central enterprises to participate in the establishment of Southern Cement, effectively integrate the cement market in Zhejiang Province, optimize the allocation of cement industry resources, and greatly improve social and economic benefits. It has a positive and far-reaching impact on the supply-side structural reform and healthy development of the cement industry in Zhejiang Province. At the same time, the long-term layout of the peak group, strategically predict the direction of national development.
2020
07-31
Jianfeng Group started from a small cement plant with an annual output of 30000 tons in 1958. Through horizontal alliance with township enterprises, the formation of enterprise groups and the implementation of joint-stock reform, Jianfeng Group took the lead in listing in China's cement industry in 1993 and explored diversified operation. In 2007, Jianfeng joined hands with the central enterprise China Building Materials to participate in the establishment of Southern Cement, which strategically shifted the focus of the cement industry, and at the same time through enterprise mergers and technological innovation, the pharmaceutical industry is growing rapidly ...... Such a long history, in the industry has a good reputation of enterprises, Zhejiang Province, the earliest existing listed companies, its head is Jiang Xiaomeng. Focus on Industry Jiang Xiaomeng has spent nearly 40 years in Jinhua Cement Factory, the predecessor of Jianfeng Group. As a witness and promoter of the development and growth of the peak, Jiang Xiaomeng said that the sustained and steady development of the peak group benefits from the long-term focus on industry, which is the value orientation of the peak and the responsibility of the enterprise. Whether there was only a single cement industry in the early stage or the diversified development after listing, all the investment projects of the peak have not left the industry. With the continuous emergence of new economic formats, many people once suggested that the peak should be transferred to the "fashionable" and rewarding industries such as the Internet, but they were all rejected. Jiang Xiaomeng explained that it is necessary to use professional people to do professional things. Peak's years of experience, talents, and resource accumulation are all in industry. Although the new format is good, it is not necessarily suitable for peak development. Take cement as an example, even in the case of peak pharmaceutical has occupied the group.
2020
07-31
Jiang Xiaomeng was selected as one of the top ten news figures in the building materials industry. "China Building Materials" magazine published an exclusive interview in August. The 8th issue of 2019 "China Building Materials" magazine published a few days ago. In the "Exclusive Perspective" column, it published an exclusive interview with Jiang Xiaomeng, the top ten news figures in the building materials industry in 2018, the party secretary and chairman of the group company. The selection of the top ten news figures in the national building materials industry initiated by "China Building Materials" magazine has established nearly a hundred shining figures in the industry since 1999, which has attracted widespread attention in the industry. The selection of the top ten news figures in the building materials industry in 2018 is described as follows: Jiang Xiaomeng is a scholar and practical outstanding entrepreneur. In 2018, with his strategic thinking of insight into the future, he united and led cadres and employees at all levels of Jianfeng Group to actively adapt to the new economic normal, focusing on deepening supply-side structural reforms, the "Belt and Road" initiative, and vigorously advocating corporate transformation and upgrading and high-quality development. Work, seize opportunities, reform and innovate, and achieve historic new achievements in the development of the peak 60 years. The group's overall economic efficiency and development quality have been significantly improved. In recent years, under the leadership of Jiang Xiaomeng, Jianfeng Group has seized the opportunity to join forces with central enterprises to participate in the establishment of Southern Cement, effectively integrate the cement market in Zhejiang Province, optimize the allocation of cement industry resources, and greatly improve social and economic benefits. It has a positive and far-reaching impact on the supply-side structural reform and healthy development of the cement industry in Zhejiang Province. At the same time, the long-term layout of the peak group, strategically predict the direction of national development.
2020
07-31
Jiang Xiaomeng was selected as one of the top ten news figures in the building materials industry. "China Building Materials" magazine published an exclusive interview in August. The 8th issue of 2019 "China Building Materials" magazine published a few days ago. In the "Exclusive Perspective" column, it published an exclusive interview with Jiang Xiaomeng, the top ten news figures in the building materials industry in 2018, the party secretary and chairman of the group company. The selection of the top ten news figures in the national building materials industry initiated by "China Building Materials" magazine has established nearly a hundred shining figures in the industry since 1999, which has attracted widespread attention in the industry. The selection of the top ten news figures in the building materials industry in 2018 is described as follows: Jiang Xiaomeng is a scholar and practical outstanding entrepreneur. In 2018, with his strategic thinking of insight into the future, he united and led cadres and employees at all levels of Jianfeng Group to actively adapt to the new economic normal, focusing on deepening supply-side structural reforms, the "Belt and Road" initiative, and vigorously advocating corporate transformation and upgrading and high-quality development. Work, seize opportunities, reform and innovate, and achieve historic new achievements in the development of the peak 60 years. The group's overall economic efficiency and development quality have been significantly improved. In recent years, under the leadership of Jiang Xiaomeng, Jianfeng Group has seized the opportunity to join forces with central enterprises to participate in the establishment of Southern Cement, effectively integrate the cement market in Zhejiang Province, optimize the allocation of cement industry resources, and greatly improve social and economic benefits. It has a positive and far-reaching impact on the supply-side structural reform and healthy development of the cement industry in Zhejiang Province. At the same time, the long-term layout of the peak group, strategically predict the direction of national development.
2020
07-30
On August 29, the group company held the 11th meeting of the 10th board of directors of the company by means of communication, and deliberated and passed the semi annual report of Jianfeng group in 2019 and the amendment of internal control system of the company. In the first half of the year, the company focused on the general work policy of "innovation and reform, integration and improvement, scientific layout, and steady development", grasping the opportunities brought by economic structure optimization and industrial upgrading externally, continuously integrating resources internally, and improving the internal management system. Improve the efficiency of enterprise operation. In the first half of 2019, the company achieved total operating income of 1.686 billion billion yuan, an increase of 12.17 percent over the same period last year, and the net profit attributable to the owners of the parent company was 0.476 billion billion yuan, an increase of 57.55 percent over the same period last year. At the end of June 2019, the Company's total assets were $5.383 billion, up 9.82 from the beginning of the year, and its net assets were $3.817 billion, up 10.64 from the beginning of the year. In the first half of the year, the company made a new breakthrough in the expansion of cement business. The group company has completed the acquisition of 100 equity of Guizhou huangpinggu longmingchuan cement co., ltd. and continues to invest in the construction of its new dry cement production line with a daily output of 4500 tons of cement clinker (with waste heat power generation). Yunnan Jianfeng invested 5 million yuan to participate in the establishment of Yunnan Jianfeng Da Zhan Cement Co., Ltd., which plans to build a cement clinker production line in lameng county, Xishuangxian Dai autonomous prefecture by capacity replacement according to relevant national policies. The company's cement subsidiaries continue to carry out in-depth "three down three improve" activities, stable.
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page